From the Mayo Center for Sleep Medicine (S.J.M., G.M.T., D.J.S., P.C.T., K.L.J., A.R.M., R.S., M.M.M., B.F.B., M.H.B., E.K.S.L.) and Departments of Neurology (S.J.M., P.V., B.F.B., M.H.S., E.K.S.L.), Health Science Research (R.S., M.M.M.), Psychology (M.M.M.), Radiology (K.K.), and Medicine (E.K.S.L.), Mayo Clinic and Foundation, Rochester, MN; Department of Neurology (H.-Y.J.), Providence Neurological Specialties-West, Portland, OR; and University of Minnesota Duluth (A.R.M.).
Neurology. 2020 Jan 7;94(1):e15-e29. doi: 10.1212/WNL.0000000000008694. Epub 2019 Dec 12.
To determine whether quantitative polysomnographic REM sleep without atonia (RSWA) distinguishes between cognitive impairment phenotypes.
Neurodegenerative cognitive impairment in older adults predominantly correlates with tauopathy or synucleinopathy. Accurate antemortem phenotypic diagnosis has important prognostic and treatment implications; additional clinical tools might distinguish between dementia syndromes.
We quantitatively analyzed RSWA in 61 older adults who underwent polysomnography including 46 with cognitive impairment (20 probable synucleinopathy), 26 probable non-synucleinopathy (15 probable Alzheimer disease, 11 frontotemporal lobar dementia), and 15 age- and sex-matched controls. Submentalis and anterior tibialis RSWA metrics and automated REM atonia index were calculated. Group statistical comparisons and regression were performed, and receiver operating characteristic curves determined diagnostic RSWA thresholds that best distinguished synucleinopathy phenotype.
Submentalis-but not anterior tibialis RSWA-was greater in synucleinopathy than nonsynucleinopathy; several RSWA diagnostic thresholds distinguished synucleinopathy with excellent specificity including submentalis tonic, 5.6% (area under the curve [AUC] 0.791); submentalis any, 15.0% (AUC 0.871); submentalis phasic, 10.8% (AUC 0.863); and anterior tibialis phasic, 31.4% (AUC 0.694). In the subset of patients without dream enactment behaviors, submentalis RSWA was also greater in patients with synucleinopathy than in those without synucleinopathy. RSWA was detected more frequently by quantitative than qualitative methods ( = 0.0001).
Elevated submentalis RSWA distinguishes probable synucleinopathy from probable nonsynucleinopathy in cognitively impaired older adults, even in the absence of clinical dream enactment symptoms.
This study provides Class III evidence that quantitative RSWA analysis is useful for distinguishing cognitive impairment phenotypes. Further studies with pathologic confirmation of dementia diagnoses are needed to confirm the diagnostic utility of RSWA in dementia.
确定定量 REM 睡眠无张力(RSWA)是否可区分认知障碍表型。
老年人的神经退行性认知障碍主要与 tau 病或突触核蛋白病相关。准确的生前表型诊断具有重要的预后和治疗意义;额外的临床工具可能有助于区分痴呆综合征。
我们对 61 名接受多导睡眠图检查的老年人进行了定量 RSWA 分析,其中包括 46 名认知障碍患者(20 名可能为突触核蛋白病)、26 名可能为非突触核蛋白病患者(15 名可能为阿尔茨海默病,11 名额颞叶痴呆)和 15 名年龄和性别匹配的对照者。计算颏下肌和胫骨前肌 RSWA 指标和自动 REM 弛缓指数。进行组间统计比较和回归,确定最佳区分突触核蛋白病表型的 RSWA 诊断阈值的受试者工作特征曲线。
与非突触核蛋白病相比,突触核蛋白病患者颏下肌 RSWA 更高,但胫骨前肌 RSWA 无差异;几个 RSWA 诊断阈值可很好地区分突触核蛋白病,包括颏下肌紧张性,5.6%(曲线下面积[AUC]0.791);颏下肌任何,15.0%(AUC 0.871);颏下肌阵发性,10.8%(AUC 0.863);胫骨前肌阵发性,31.4%(AUC 0.694)。在无梦境行为表现的患者亚组中,突触核蛋白病患者的颏下肌 RSWA 也高于无突触核蛋白病患者。定量方法比定性方法更能检测到 RSWA(=0.0001)。
在认知障碍的老年人中,颏下肌 RSWA 升高可区分可能的突触核蛋白病和可能的非突触核蛋白病,即使没有临床梦境行为症状。
本研究提供了 III 级证据,表明定量 RSWA 分析有助于区分认知障碍表型。需要进一步的研究,以病理确认痴呆诊断,以证实 RSWA 在痴呆中的诊断效用。